genetically engineered lymphocyte therapy
Cell therapyexperimental
Clinical trial activity
3 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Aug 1, 2007 (NCT00621452)
Timeline
2000s
- Jan 1, 2007
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
- Hodgkin Disease · Phase 1
- Leukemia, Lymphocytic, Chronic, B-Cell · Phase 1
- Lymphoma, B-Cell, Marginal Zone · Phase 1
- Lymphoma, Follicular · Phase 1/Phase 2
- Lymphoma, Large-Cell, Anaplastic · Phase 1
- Lymphoma, Mantle-Cell · Phase 1/Phase 2
- Lymphoma, Non-Hodgkin · Phase 1/Phase 2
- Lymphoma, T-Cell · Phase 1
- Mycosis Fungoides · Phase 1
- Waldenstrom Macroglobulinemia · Phase 1
Mechanism of action
- Unspecified targetImmunity, passive
Immunity, passive
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- genetically engineered lymphocyte therapy
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04074746 | Phase 1 | Oct 1, 2019 | University of Texas at Houston |
| NCT01318317 | Phase 1/Phase 2 (Phase 2) | Sep 1, 2011 | City of Hope National Medical Center, National Cancer Institute (NCI) |
| NCT00621452 | Phase 1 | Aug 1, 2007 | National Cancer Institute (NCI), University of Washington |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| National Cancer Institute (NCI) | Government | 2 | 0 | 2 | 2007 |
| City of Hope National Medical Center | Academic/Hospital | 1 | 1 | 1 | 2011 |
| University of Texas at Houston | Academic/Hospital | 1 | 1 | 1 | 2019 |
| University of Washington | Academic/Hospital | 1 | 1 | 1 | 2007 |
4 organizations
Page 1 / 1